Non-invasive imaging biomarkers for nonalcoholic steatohepatitis (NASH) clinical drug development are widely used to study the effects of investigational products on the degree of steatosis, inflammation and fibrosis of the liver. This webinar will discuss the selection and application of imaging modalities to measure target engagement and mechanism-of-action in metabolically active organs, including the liver, adipose tissue, pancreas, skeletal muscle, heart and kidney, when designing and conducting NASH clinical trials.
This webinar is the first in a collaborative series hosted by ProSciento, Inc. and the NASH Roundtable™ and focused on the advancement and application of scientific methods and strategies for NASH clinical research.
Recommended Materials
Posters
Application of a Non-Invasive Integrated Screening Algorithm to Improve Enrollment in NAFLD/NASH Clinical Trials
Posters
Relationship Between Controlled Attenuation Parameter (CAP) and Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) in Subjects at High Risk for Nonalcoholic Fatty Liver Disease (NAFLD)
Posters
Application of a Non-Invasive Integrated Screening Algorithm to Improve Enrollment in NAFLD/NASH Clinical Trials
Related Solutions
Specialized Methods
